

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Scoping

#### STA Ciplagucosidase alfa with miglustat for treating Pompe disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- Ensure no patient has to travel excessive distance to receive treatment given the level of disability that many will face
- Consider BAME groups – possible that genetic, recessive condition has higher prevalence in communities with consanguineous marriage
- Noted that bulbar weakness is common in Pompe disease with a request to understand how some people would ingest the miglustat pill.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

- Issues related to ease of access – The committee will be made aware of this
- Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal
- Issue related to bulbar weakness – The committee will be made aware of this and further information should be provided in the summary of product characteristics

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified and no changes to the matrix have been made.

**Approved by Associate Director (name):** Janet Robertson

**Date:** 22 August 2022